Trevi Therapeutics, Inc. (TRVI) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on January 8, 2025, by Trevi Therapeutics, Inc., a Delaware corporation. The filing provides company updates in advance of the 14th Annual LifeSci Partners Corporate Access Event and the J.P. Morgan Healthcare Conference. The report focuses on clinical trial progress and a preliminary liquidity update as of December 31, 2024.
Key Financial Metrics
- Liquidity: The Company estimates its cash, cash equivalents, and marketable securities were $107.6 million as of December 31, 2024.
- Audit Status: This liquidity figure is a preliminary estimate based on information available as of the filing date. It has not been audited or reviewed by the Company's independent registered public accounting firm.
- Revenue and Profit: The filing text does not provide specific values for revenue, profit, cash flow, margins, or debt for the reporting period.
Material Changes and Clinical Updates
The filing details significant progress in two key clinical trials:
- Phase 2a RIVER Trial (Refractory Chronic Cough): The last patient completed their final visit in early January 2025. The trial was designed to enroll approximately 60 patients. Topline results are expected in the first quarter of 2025.
- Phase 2b CORAL Trial (Idiopathic Pulmonary Fibrosis with Chronic Cough): A sample size re-estimation analysis announced in December 2024 reaffirmed the original sample size of 160 patients. The trial is approximately 80% enrolled, with topline results expected in the first half of 2025.
Outlook, Risks, and Management Commentary
Management provided forward-looking statements regarding the development of its product candidate, Haduvio, and the Company's expected cash runway. The filing includes standard disclaimers that actual results may differ materially from expectations due to various risks, including:
- Uncertainties regarding the success, cost, and timing of clinical trials.
- The risk that positive data from earlier trials may not predict results in later trials.
- Regulatory authorities' views on clinical data and future development paths.
- Uncertainties in estimating future expenses and the ability to fund ongoing operations.
The Company explicitly states it undertakes no obligation to update these forward-looking statements.
Investor Verification Checklist
- Verify the final audited cash, cash equivalents, and marketable securities balance in the upcoming Form 10-K, as the $107.6 million figure is unaudited and preliminary.
- Monitor the release of topline results for the Phase 2a RIVER trial (expected Q1 2025) and the Phase 2b CORAL trial (expected H1 2025).
- Review the Company's most recent Form 10-Q (ended September 30, 2024) for detailed historical financial data, as this 8-K does not contain revenue or expense figures.
- Assess the Company's cash runway relative to the anticipated costs of completing the CORAL trial and any subsequent regulatory filings.